ArticleCureus2025
Hip Fractures and Hypogonadism in Young Males: A Missed Opportunity for Secondary Prevention?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLow testosterone is a known risk factor for osteoporosis and fragility fractures in men. Unlike in women, osteoporosis in men often presents later in life. Fragility hip fractures in males under 60 years are uncommon and may represent an opportunity to diagnose and treat an underlying metabolic bone pathology. This study aims to evaluate whether low-energy hip fractures in young men are associated with low serum testosterone. MATERIALS AND
methodsWe performed a retrospective review of a prospectively maintained database, identifying male patients aged <60 years who sustained hip fractures from low-energy trauma between January 2022 and December 2024. Fractures up to 5 cm distal to the lesser trochanter were included. Demographic, comorbidity, and laboratory data were collected; serum testosterone <198 pmol/L was defined as low.
resultsSixty-one males (mean age 50.6 ± 7.2 years) sustained hip fractures in this study period; 23 (38%) had serum testosterone measured. Of those, 15 (65%) were found to have low testosterone; only one had a known endocrine disorder. Among the total cohort, 42 (69%) had multiple comorbidities, 24 (39%) were on polypharmacy (≥5 medications), 25 (41%) were current smokers, 17 (28%) reported excessive alcohol use, and 13 (21%) had a history of substance misuse.
conclusionsA substantial proportion of young men with fragility hip fractures had unrecognized low testosterone levels. These findings indicate that hormonal abnormalities may be under-recognized in this population, and further studies are warranted to determine whether targeted hormonal screening could help reduce future fragility fracture risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.